184 related articles for article (PubMed ID: 30276862)
1. Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.
Lange NW; Salerno DM; Sammons CM; Jesudian AB; Verna EC; Brown RS
Clin Transplant; 2018 Dec; 32(12):e13415. PubMed ID: 30276862
[TBL] [Abstract][Full Text] [Related]
2. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Verna EC; Farrand ED; Elnaggar AS; Pichardo EM; Balducci A; Emond JC; Guarrera JV; Brown RS
Transplantation; 2011 Jun; 91(11):1254-60. PubMed ID: 21617588
[TBL] [Abstract][Full Text] [Related]
3. Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates.
Kim HE; Paik HC; Jeong SJ; Park MS; Kim SY; Lee JG
Yonsei Med J; 2021 Feb; 62(2):164-171. PubMed ID: 33527796
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.
Hashim M; Alsebaey A; Ragab A; Soliman HE; Waked I
Ann Hepatol; 2020; 19(5):541-545. PubMed ID: 32768592
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study.
Sterneck M; Kaiser GM; Heyne N; Richter N; Rauchfuss F; Pascher A; Schemmer P; Fischer L; Klein CG; Nadalin S; Lehner F; Settmacher U; Gotthardt D; Loss M; Ladenburger S; Wimmer P; Dworak M; Schlitt HJ
Clin Transplant; 2016 Jun; 30(6):741-8. PubMed ID: 27160359
[TBL] [Abstract][Full Text] [Related]
6. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
Cillo U; Bechstein WO; Berlakovich G; Dutkowski P; Lehner F; Nadalin S; Saliba F; Schlitt HJ; Pratschke J
Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
[TBL] [Abstract][Full Text] [Related]
7. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
Bajjoka I; Hsaiky L; Brown K; Abouljoud M
Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
[TBL] [Abstract][Full Text] [Related]
8. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
9. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
Mundisugih J; Fernando H; Bergin P; Hare J; Kaye D; Leet A; McGiffin D; Taylor AJ
Prog Transplant; 2019 Dec; 29(4):327-334. PubMed ID: 31476958
[TBL] [Abstract][Full Text] [Related]
10. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
12. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial.
Saliba F; Duvoux C; Gugenheim J; Kamar N; Dharancy S; Salamé E; Neau-Cransac M; Durand F; Houssel-Debry P; Vanlemmens C; Pageaux G; Hardwigsen J; Eyraud D; Calmus Y; Di Giambattista F; Dumortier J; Conti F
Am J Transplant; 2017 Jul; 17(7):1843-1852. PubMed ID: 28133906
[TBL] [Abstract][Full Text] [Related]
14. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
[TBL] [Abstract][Full Text] [Related]
15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
16. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.
Schnitzbauer AA; Scherer MN; Rochon J; Sothmann J; Farkas SA; Loss M; Geissler EK; Obed A; Schlitt HJ
BMC Nephrol; 2010 Sep; 11():24. PubMed ID: 20840760
[TBL] [Abstract][Full Text] [Related]
17. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
Arora N; McKiernan PJ; Beath SV; deVille de Goyet J; Kelly DA
Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
